Extracellular matrix integrity: A possible mechanism for differential clinical effects among selective estrogen receptor modulators and estrogens?

Molecular and Cellular Endocrinology

Volumn 247, Issue 1-2, 2006, Pages 53-59

  Cox, David A ^a   Helvering, Leah M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Estrogen; Extracellular matrix; Matrix metalloproteinase; Raloxifene; Selective estrogen receptor modulator; Uterus

Indexed keywords

CENTCHROMAN; ESTROGEN; IDOXIFENE; MATRIX METALLOPROTEINASE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CARCINOMA; CLINICAL TRIAL; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; LIGAND BINDING; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; PELVIC ORGAN PROLAPSE; PRIORITY JOURNAL; REVIEW; URINE INCONTINENCE; UROGENITAL SYSTEM; UTERUS; VAGINA;

ANIMALS; CYSTS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; HUMANS; HYPERPLASIA; METALLOENDOPEPTIDASES; POLYPS; POSTMENOPAUSE; RATS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; URINARY INCONTINENCE; UTERINE PROLAPSE; UTERUS;

EID: 33244465586     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2005.12.020     Document Type: Review

References (58)

1. S.M. Abbas Abidi, E.W. Howard, J.J. Dmytryk, and J.T. Pento Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells Clin. Exp. Metastasis 15 1997 432 439
2. J.A. Ardans, A. Blum, P.R. Mangan, S. Wientroub, R.O. Cannon III, and L.M. Wahl Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes Arterioscler. Thromb. Vasc. Biol. 21 2001 1265 1268
3. A. Blum, W.H. Schenke, L. Hathaway, R. Mincemoyer, G. Csako, M.A. Waclawiw, and R.O. Cannon Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women Am. J. Cardiol. 86 2000 892 895
4. S.M. Boss, W.J. Huster, J.A. Neild, M.D. Glant, C.C. Eisenhut, and M.W. Draper Effects of raloxifene hydrochloride on the endometrium of postmenopausal women Am. J. Obstet. Gynecol 177 1997 1458 1464
5. B.H. Chen, Y. Wen, H. Li, and M.L. Polan Collagen metabolism and turnover in women with stress urinary incontinence and pelvic prolapse Int. Urogynecol. J. Pelvic Floor Dysfunct. 13 2002 80 87
6. I. Cohen Endometrial pathologies associated with postmenopausal tamoxifen treatment Gynecol. Oncol. 94 2004 256 266
7. S. Cummings, S. Eckert, K. Krueger, D. Grady, T. Powles, J. Cauley, L. Norton, T. Nickelsen, N. Bjarnason, M. Morrow, M. Lippman, D. Black, J. Glusman, A. Costa, and V.C. Jordan The effect of raloxifene on risk of breast cancer in postmenopausal women JAMA 281 1999 2189 2197
8. C. Falconer, G. Ekman-Ordeberg, B. Blomgren, O. Johansson, U. Ulmsten, G. Westergren-Thorsson, and A. Malmstrom Paraurethral connective tissue in stress-incontinent women after menopause Acta Obstet. Gynecol. Scand. 77 1998 95 100
9. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, W.M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, and N. Wolmark Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer. Inst. 90 1998 1371 1388
10. B. Fisher, J. Dignam, J. Bryant, and N. Wolmark Five versus more than five years of tamoxifen for lumph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial J. Natl. Cancer Inst. 93 2001 684 690
11. A.C. Fleischer, J.E. Wheeler, I.T. Yeh, B. Kravitz, C. Jensen, and B. MacDonald Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene J. Ultrasound Med. 18 1999 503 512
12. J. Frasor, F. Stossi, J.M. Danes, B. Komm, C.R. Lyttle, and B.S. Katzenellenbogen Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells Cancer Res. 64 2004 1522 1533
13. Z.S. Galis, and J.J. Khatri Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly Circ. Res. 90 2002 251 262
14. S.R. Goldstein, W.H. Scheele, S.K. Rajagopalan, J.L. Wilkie, B.W. Walsh, and A.K. Parsons A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium Obstet. Gynecol. 95 2000 95 103
15. S.R. Goldstein, S. Johnson, N.B. Watts, A.V. Ciaccia, D. Elmerick, and D. Muram Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen Menopause 12 2005 160 164
16. S.R. Goldstein, and N. Nanavati Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study Am. J. Obstet. Gynecol. 187 2002 521 527
17. S.R. Goldstein, P. Neven, L. Zhou, Y.L. Taylor, A.V. Ciaccia, and L. Plouffe Raloxifene effect on frequency of surgery for pelvic floor relaxation Obstet. Gynecol. 98 2001 91 96
18. D. Grady, J.S. Brown, E. Vittinghoff, W. Applegate, E. Varner, and T. Snyder Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study Obstet. Gynecol. 97 2001 116 120
19. D. Grady, T. Gebretsadik, K. Kerlikowske, V. Ernster, and D. Petitti Hormone replacement therapy and endometrial cancer risk: a meta-analysis Obstet. Gynecol. 85 1995 304 313
20. L.M. Helvering, M.D. Adrian, A.G. Geiser, S.T. Estrem, T. Wei, S. Huang, P. Chen, E.R. Dow, J.N. Calley, J.A. Dodge, T.A. Grese, S.A. Jones, D.L. Halladay, R.R. Miles, J.E. Onyia, Y.L. Ma, M. Sato, and H.U. Bryant Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus Biol. Reprod. 72 2005 830 841
21. S.L. Hendrix, B.B. Cochrane, I.E. Nygaard, V.L. Handa, V.M. Barnabei, C. Iglesia, A. Aragaki, M.J. Naughton, R.B. Wallace, and S.G. McNeeley Effects of estrogen with and without progestin on urinary incontinence JAMA 293 2005 935 948
22. S.L. Hendrix, and S.G. McNeeley Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium Ann. N. Y. Acad. Sci. 949 2001 243 250
23. K. Hisamoto, and J.R. Bender Vascular cell signaling by membrane estrogen receptors Steroids 70 2005 382 387
24. Hu, P., Greendale, G.A., Palla, S.L., Reboussin, B.A., Herrington, D.M., Barrett-Connor, E., Reuben, D.B. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis. doi:10.1016/j.atherosclerosis.2005. 06.011 (Epub ahead of print), in press.
25. H.F. Huang, L.H. Hong, Y. Tan, and J.Z. Sheng Matrix metalloproteinase 2 is associated with changes in steroid hormones in the sera and peritoneal fluid of patients with endometriosis Fertil. Steril. 81 2004 1235 1239
26. S.R. Jackson, N.C. Avery, J.F. Tarlton, S.D. Eckford, P. Abrams, and A.J. Bailey Changes in metabolism of collagen in genitourinary prolapse Lancet 347 1996 1658 1661
27. S. Jackson, M. James, and P. Abrams The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence BJOG 109 2002 339 344
28. E.E. Jolly, N.H. Bjarnason, P. Neven, L. Plouffe Jr., C.C. Johnston Jr., S.D. Watts, C.D. Arnaud, T.M. Mason, G. Crans, R. Akers, and M.W. Draper Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years Menopause 10 2003 337 344
29. T.M. Kian, I. Rogatsky, C. Tzagarakis-Foster, A. Cvoro, J. An, R.J. Christy, K.R. Yamamoto, and D.C. Leitman Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta Mol. Biol. Cell 15 2004 1262 1272
30. S. Leppa, T. Saarto, L. Vehmanen, C. Blomqvist, and I. Elomaa A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma Clin. Cancer Res. 10 2004 1057 1063
31. A.S. Levenson, K.M. Svoboda, K.M. Pease, S.A. Kaiser, B. Chen, L.A. Simons, B.D. Jovanovic, P.A. Dyck, and V.C. Jordan Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor Cancer Res. 62 2002 4419 4426
32. H.C. Li, D.C. Cao, Y. Liu, Y.F. Hou, J. Wu, J.S. Lu, G.H. Di, G. Liu, F.M. Li, Z.L. Ou, C. Jie, Z.Z. Shen, and Z.M. Shao Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma Breast Cancer Res. Treat. 88 2004 75 85
33. L.A. Liotta, and W.G. Stetler-Stevenson Metalloproteinases and cancer invasion Semin. Cancer Biol. 1 1990 99 106
34. M.E. Marin-Castano, S.J. Elliot, M. Potier, M. Karl, L.J. Striker, G.E. Striker, K.G. Csaky, and S.W. Cousins Regulation of estrogen receptors and MMP-2 expression by estrogens in human retinal pigment epithelium Invest. Ophthalmol. Vis. Sci. 44 2003 50 59
35. S. Martino, J.A. Cauley, E. Barrett-Connor, T.J. Powles, J. Mershon, D. Disch, R.J. Secrest Cummings S for the CORE Investigators Continuing outcomes relevant to evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J. Natl. Cancer Inst. 96 2004 1751 1761
36. S. Martino, D. Disch, S.A. Dowsett, C.A. Keech, and J. Mershon Safety assessment of raloxifene over eight years in a clinical trial setting Curr. Med. Res. Opin. 21 2005 1441 1452
37. D.P. McDonnell The molecular determinants of estrogen receptor pharmacology Maturitas 48 Suppl. 1 2004 S7 S12
38. T.N. Mitropoulou, G.N. Tzanakakis, D. Kletsas, H.P. Kalofonos, and N.K. Karamanos Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells Int. J. Cancer 104 2003 155 160
39. B. Moehrer, A. Hextall, and S. Jackson Oestrogens for urinary incontinence in women Cochrane Database Syst. Rev. 2003 CD001405
40. PEPI Trial Writing Group Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial JAMA 275 1996 370 375
41. M. Potier, S.J. Elliot, I. Tack, O. Lenz, G.E. Striker, L.J. Striker, and M. Karl Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9 J. Am. Soc. Nephrol. 12 2001 241 251
42. S.M. Ranuncolo, E. Armanasco, C. Cresta, J.E. Bal De Kier, and L. Puricelli Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients Int. J. Cancer 106 2003 745 751
43. J.E. Rossouw Early risk of cardiovascular events after commencing hormone replacement therapy Curr. Opin. Lipidol. 12 2001 371 375
44. K. Sak, and H. Everaus Nongenomic effects of 17beta-estradiol - diversity of membrane binding sites J. Steroid Biochem. Mol. Biol. 88 2004 323 335
45. R.V. Sclafani, and D.L. Wendell Suppression of estrogen-dependent MMP-9 expression by Edpm5, a genetic locus for pituitary tumor growth in rat Mol. Cell Endocrinol. 176 2001 145 153
46. S.L. Silfen, A.V. Ciaccia, and H.U. Bryant Selective estrogen receptor modulators: tissue specificity and differential uterine effects Climacteric 2 1999 268 283
47. A. Surazynski, K. Jarzabek, J. Haczynski, P. Laudanski, J. Palka, and S. Wolczynski Differential effects of estradiol and raloxifene on collagen biosynthesis in cultured human skin fibroblasts Int. J. Mol. Med. 12 2003 803 809
48. E. Vegeto, C. Bonincontro, G. Pollio, A. Sala, S. Viappiani, F. Nardi, A. Brusadelli, B. Viviani, P. Ciana, and A. Maggi Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia J. Neurosci. 21 2001 1809 1818
49. E. Vegeto, S. Ghisletti, C. Meda, S. Etteri, S. Belcredito, and A. Maggi Regulation of the lipopolysaccharide signal transduction pathway by 17beta-estradiol in macrophage cells J. Steroid Biochem. Mol. Biol. 91 2004 59 66
50. L.E. Waetjen, J.S. Brown, K. Modelska, T. Blackwell, E. Vittinghoff, and S.R. Cummings Effect of raloxifene on urinary incontinence: a randomized controlled trial Obstet. Gynecol. 103 2004 261 266
51. A. Wakatsuki, N. Ikenoue, K. Shinohara, K. Watanabe, and T. Fukaya Different effects of oral and transdermal estrogen replacement therapy on matrix metalloproteinase and their inhibitor in postmenopausal women Arterioscler. Thromb. Vasc. Biol. 23 2003 1948 1949
52. L. Warming, C. Christoffersen, B.J. Riis, J.A. Stakkestad, P.D. Delmas, and C. Christiansen Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal Maturitas 44 2003 189 199
53. A.M. Weber, G.M. Buchsbaum, B. Chen, A.L. Clark, M.S. Damaser, F. Daneshgari, G. Davis, J. DeLancey, K. Kenton, A.C. Weidner, and R.A. Word Basic science and translational research in female pelvic floor disorders: proceedings of an NIH-sponsored meeting Neurourol. Urodyn. 23 2004 288 301
54. C.S. Wingrove, E. Garr, I.F. Godsland, and J.C. Stevenson 17Beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells Biochim. Biophys. Acta 1406 1998 169 174
55. S. Wolczynski, A. Surazynski, J. Swiatecka, and J. Palka Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells Gynecol. Endocrinol. 15 2001 225 233
56. D. Zanger, B.K. Yang, J. Ardans, M.A. Waclawiw, G. Csako, L.M. Wahl, and R.O. Cannon III Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management J. Am. Coll. Cardiol. 36 2000 1797 1802
57. P. Zhang, and M. Zhong Effects of 17beta-estradiol and progesterone on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in rat osteoblasts Di Yi. Jun. Yi. Da. Xue. Xue. Bao. 21 2001 929 931
58. Y. Zhang, K.G. Stewart, and S.T. Davidge Estrogen replacement reduces age-associated remodeling in rat mesenteric arteries Hypertension 36 2000 970 974